Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

05/03/2013 | 08:40am US/Eastern
Recommend:
0
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
Zogenix
distributed by
Recommend :
0
React to this article
Latest news
Date Title
1m ago TELKOM SOC : first FTTH suburbs live by end-2014
1m ago TELEFONICA : ICE, Telefonica amongst those linked with possible Hondutel investment
1m ago CITIGROUP : August PMI suggests easing policy bias to stay
1m ago M Dream Inworld (08100) to change name to "GET Holdings"
1m ago CHINA GALAXY SECURITIES : CGS completes Rmb2.4bn short-term subordinate bonds issue
1m ago LEE PHARMACEUTICAL : Pharm to change board lot size to 500 shares
1m ago BHARTI AIRTEL : All four cellcos fined by regulator
1m ago SKT, KT and LG Uplus reduce new mobile customer registration charges
1m ago MOODY : Fosun's weak performance pressures credit profile - Moody's
1m ago UOB KAY HIAN : UOBKH lowers China BlueChem to HK$5.3
Latest news
Advertisement
Hot News 
CORRECT : Dixons Carphone Confirms Long Term Deal With Vodafone
CRANEWARE : Issue of Consideration Shares
FINTECH : announces new CEO and designated Chairman (DGAP News)
ASCENT SOLAR TECHNOLOGIES : Announces New Common Stock Investment of $8.0 Million Led by Largest Shareholder, TFG Radiant Investment Group
VISLINK : Chairman Buys 95,157 Shares (DIRECTOR DEALINGS)
Most Read News
1d ago FORMFACTOR : Raises Third Quarter Guidance Range
1d ago STUART OLSON : announces sale of Broda Construction
1d ago MEDICINOVA : to Present Data on MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) During the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF)
5h ago MANCHESTER UNITED : Van Gaal Speaks on Di Maria Injury
1d ago EXELIXIS : Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate Cancer
Most recommended articles
1d agoDJZambia Copper Miners Say Crippled by Unpaid $600 Million Tax Refund-Mines Body
4d ago S&P 500 edges up to set new record; best month since Feb
2m agoDJAutoZone to Acquire Interamerican Motor
3m ago UK to deliver budget statement on December 3 - Osborne
9m ago Futures point to higher open for TSX
Dynamic quotes  
ON
| OFF